---
figid: PMC9357610__JCMM-26-4548-g004
pmcid: PMC9357610
image_filename: JCMM-26-4548-g004.jpg
figure_link: /pmc/articles/PMC9357610/figure/jcmm17478-fig-0004/
number: FIGURE 4
figure_title: ''
caption: 'Pirfenidone regulated the TGF‐β1/Smad3 signalling pathway. (A–D) Western
  blotting and relative expression of TGF‐β1 in mouse heart (n = 5–6) and primary
  cardiac fibroblasts (CFs) (n = 4), respectively. (E–H) Western blotting and relative
  expression of p‐Smad3, Smad3 in mouse heart (n = 5–6) and CFs (n = 4), respectively.
  (I–L) Western blotting and relative expression of Smad7 in mouse heart (n = 5–6)
  and CFs (n = 4), respectively. *p < 0.05, **p < 0.01 vs. Sham/Ctrl group; #p < 0.05,
  ##p < 0.01 vs. TAC/AngII group'
article_title: Pirfenidone alleviates cardiac fibrosis induced by pressure overload
  via inhibiting TGF‐β1/Smad3 signalling pathway.
citation: Na Li, et al. J Cell Mol Med. 2022 Aug;26(16):4548-4555.
year: '2022'

doi: 10.1111/jcmm.17478
journal_title: Journal of Cellular and Molecular Medicine
journal_nlm_ta: J Cell Mol Med
publisher_name: John Wiley and Sons Inc.

keywords:
- cardiac fibrosis
- cardiac remodelling
- pirfenidone
- pressure overload
- transforming growth factor‐β1

---
